Since 2004, EMO Biomedicine and its founder Dr. Shing-Mao Lee have been at the forefront of Taiwan’s cell therapy evolution. As one of the earliest experts in the field, Dr. Lee played a crucial role in shaping cell quality inspection standards and ensuring safe, functional cell-based therapies.

His contributions include:

• Leading Taiwan’s GTP (Good Tissue Practice) implementation
• Guiding the CPU (Cell Processing Unit) framework under the Special Regulations for Cell Therapy
• Collaborating with top cell therapy startups & clinical developers

With a background from Kitasato University in Japan, Dr. Lee has championed the belief that cell therapies are only as good as their quality control. Today, he remains a driving force behind Taiwan’s booming regenerative medicine industry.

Read more: http://bit.ly/v119people

Follow #Globalbio for the latest biotech & regenerative medicine insights!

#CellTherapy #RegenerativeMedicine #QualityControl #BiotechInnovation #GTP #CPU #TaiwanBiotech #Globalbio #FutureOfMedicine